Search Videos and More
Putting the Nurse Back into Nurse Navigation
More than 15 years ago, Fox Chase Cancer Center launched a Nurse Navigation system to expedite the journey through complex cancer care with experienced oncologic nurses as a patient’s first 'point-of-contact' via phone.HER2-Targeted Agents: Not Just for Breast Cancer
With 20% of breast cancers driven by alterations to the HER2 gene, inhibiting the expression of this gene has been an objective of researchers and clinicians for decades, and a number of inhibitory therapies have been developed.Harnessing the Power of Adaptive Radiation Therapy: A One-Year Review from Fox Chase Cancer Center
Over the past year, the Fox Chase Cancer Center Radiation Oncology team led by Eric Horwitz, MD, FABS, FASTRO, Chair of the Department of Radiation Oncology at Fox Chase and the Lewis Katz School of Medicine at Temple University, has boldly moved adaptive radiation therapy into the mainstream, demonstrating its clinical advantages for treating prostate, bladder, liver, pancreas, breast, lung, and head and neck cancers.Mapping a Path to Clinical Trials: Bringing Fox Chase’s Innovative Care to the Temple Community
Clinical trials are among the most important resources when it comes to effectively treating challenging cases of cancer, but at Fox Chase Cancer Center, these trials encompass much more than just testing new drug candidates that may be more effective alternative treatments.Fox Chase Fellows – Winter 2024
People say you never really leave Fox Chase. Just ask Matt Zibelman, MD, who was a Fox Chase hematology/oncology fellow and now is the GU Service Line Director of Clinical and Translational Research—or his colleague Mark Hallman, MD, PhD, a former Fox Chase Radiation Oncology resident, now serving as the GU Service Line Clinical DirectorMany Legacies to Carry On
In May 2023, Michael O. Meyers, MD, a surgical oncologist at UNC, was named the James F. and Alice B. Newsome Distinguished Professor.Fox Chase Researcher’s Presentation Highlights Unique Approach to Esophagectomy at American College of Surgeons Clinical Congress
Nosayaba Enofe, MD, presented his experience with a unique minimally invasive hybrid approach to esophagectomy at the American College of Surgeons Clinical Congress.22nd Annual Highlights of the 2023 San Antonio Breast Cancer Symposium
New Directions in the Diagnosis and Treatment of Hematologic Cancers
DATE: Tuesday, April 16, 2024Inspiring Residents to Climb Higher
When asked why he chose Fox Chase Cancer Center for his urologic surgery fellowship (2019-2021), Marshall Strother, MD, responds, “I liked the way ‘Fox,’ as he calls Fox Chase, has an exacting, intentional, and deliberate method of training. Hierarchies are flattened there, allowing new surgeons to work and learn with the most experienced on the team.”Recognizing International Excellence
Fox Chase Cancer Center is known around the world as an international leader in bold urologic cancer care, scientific research, translational research, and education. These are the people whose accomplishments make it happen.Adstiladrin (Nadofaragene Firadenovec-vncg): The First Intravesical Gene Therapy for Bladder Cancer Now Available at Fox Chase
Eligible patients will now have access to the first FDA-approved intravesical gene therapy for non-muscle invasive bladder cancer (NMIBC) at Fox Chase Cancer Center.